<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1796">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04542993</url>
  </required_header>
  <id_info>
    <org_study_id>SHS KAPH NSWE 20090</org_study_id>
    <nct_id>NCT04542993</nct_id>
  </id_info>
  <brief_title>Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy</brief_title>
  <acronym>Reszinate</acronym>
  <official_title>Can SARS-CoV-2 Viral Shedding in COVID-19 Disease be Reduced by Resveratrol-assisted Zinc Ingestion, a Direct Inhibitor of SARS-CoV-2-RNA Polymerase? A Single Blinded Phase II Protocol (Reszinate Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swedish Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swedish Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Administration of Zinc and resveratrol or double placebo for a period of 5 days and will be&#xD;
      monitored for a 14 day period in covid-19 positive patients in an outpatient setting&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Research Question: In ambulatory, non-hospitalized patients with SARS-CoV-2 infection, is it&#xD;
      possible to utilize resveratrol as a transporter for zinc treatment as means to minimize&#xD;
      viral load and severity of resulting COVID-19 disease?&#xD;
&#xD;
      60 ambulatory SARS-CoV-2 positive volunteers who will be randomized into one of two treatment&#xD;
      arms to receive either Zinc and resveratrol or double placebo for a period of 5 days and will&#xD;
      be monitored for a 14 day period. It is anticipated to take approximately 20 weeks to accrue&#xD;
      this cohort resulting in an estimated active project period of 22 weeks, although it may take&#xD;
      up to 12 additional weeks to collect all of the data related to COVID-19 admissions in the&#xD;
      cohort.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 8, 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Placebo controlled Resveratrol and Zinc combination therapy</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>single blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in SARS-CoV-2 Viral load</measure>
    <time_frame>1 year</time_frame>
    <description>Viral AUCs normalized to peak viral load and housekeeper genes will be calculated, the AUCs on subjects with complete data will be used as dependent measures in t-tests, regressions and repeated measures mixed ANOVAs to compare viral load reduction between groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction in Severity of COVID-19 Disease</measure>
    <time_frame>1 year</time_frame>
    <description>Review of healthcare resource utilization during study period</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Covid19</condition>
  <condition>SARS-CoV Infection</condition>
  <arm_group>
    <arm_group_label>Resveratrol and Zinc Picolinate combination therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Resveratrol and Zinc Picolinate combination therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Resveratrol Placebo and Zinc Placebo combination therapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Resveratrol and Placebo Zinc combination therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Zinc Picolinate</intervention_name>
    <description>Zinc Picolinate (50 mg PO TID x 5 days)</description>
    <arm_group_label>Resveratrol and Zinc Picolinate combination therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Resveratrol</intervention_name>
    <description>Resveratrol 2 grams po BID x 5 days</description>
    <arm_group_label>Resveratrol and Zinc Picolinate combination therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Zinc Picolinate Placebo</intervention_name>
    <description>Zinc Picolinate Matched Placebo PO TID x 5 days</description>
    <arm_group_label>Resveratrol Placebo and Zinc Placebo combination therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Resveratrol Placebo</intervention_name>
    <description>Resveratrol Matched Placebo PO BID x 5 days</description>
    <arm_group_label>Resveratrol Placebo and Zinc Placebo combination therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults (18 - 75) with a nasal swab confirmed SARS-CoV-2 infection; testing positive&#xD;
             within 4 days of enrollment&#xD;
&#xD;
          2. Ability to read, understand and provide informed consent (no legally authorized&#xD;
             representatives may consent on their behalf) and study assessments in English&#xD;
&#xD;
          3. Ability for subject to comply with the requirements of the study (must/will have a&#xD;
             valid email address, internet connection and phone number)&#xD;
&#xD;
          4. Willingness to self limit medications and supplements and report what they are taking&#xD;
&#xD;
          5. Comfortable self-administering oral medication and nasal swab sampling&#xD;
&#xD;
          6. Willingness to permit a review of their medical history and to provide medical data&#xD;
             from their electronic medical record for the period of enrollment (14 days) and until&#xD;
             resolution of Covid-19 related events. Individuals who are not current Swedish&#xD;
             patients will be asked to identify their provider of record and provide access to&#xD;
             specific elements of their electronic health record.&#xD;
&#xD;
          7. Reside within twenty-five miles of one of the Swedish campuses: First Hill, Ballard,&#xD;
             Edmonds, Issaquah, Cherry Hill.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Reported history or evidence of impaired liver or kidney function: GFR &lt;30 or&#xD;
             bilirubin &gt;2x ULT or INR &gt; 2x ULT in the absence of anticoagulants&#xD;
&#xD;
          2. Known hypersensitivity to zinc or resveratrol&#xD;
&#xD;
          3. Diagnosis of COVID-19 or SARS-CoV-2 infection &gt;4 days before enrollment&#xD;
&#xD;
          4. Preexisting severe pulmonary disease requiring supplemental oxygen&#xD;
&#xD;
          5. Clinically evident impairment of cognitive function, per physician discretion&#xD;
&#xD;
          6. Active substance abuse that may prevent the subject from completing the protocol&#xD;
             requirements, per physician discretion.&#xD;
&#xD;
          7. Active psychotic or affective disorder that may prevent the subject from completing&#xD;
             the protocol requirements, per physician discretion.&#xD;
&#xD;
          8. Pregnant or lactating females.&#xD;
&#xD;
          9. Coumadin treatment that can not be halted during the study period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chris Nunn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Swedish Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cancer Research</last_name>
    <phone>206-215-3086</phone>
    <email>CancerResearch@swedish.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cancer Regulatory</last_name>
    <email>CancerRegulatory@swedish.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hank Kaplan, MD</last_name>
      <phone>206-998-4664</phone>
      <email>Research.Center@Swedish.org</email>
    </contact>
    <investigator>
      <last_name>Hank Kaplan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chris Nunn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 8, 2020</study_first_submitted>
  <study_first_submitted_qc>September 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2020</study_first_posted>
  <last_update_submitted>October 14, 2020</last_update_submitted>
  <last_update_submitted_qc>October 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>covid19</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>zinc</keyword>
  <keyword>resveratrol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zinc</mesh_term>
    <mesh_term>Resveratrol</mesh_term>
    <mesh_term>Picolinic acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Currently no plan to make IPD available</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

